Empirical treatment of candidemia in intensive care units: Fluconazole or broad-spectrum antifungal agents?

Medical Mycology

Volumn 47, Issue 5, 2009, Pages 515-520

  Guinea, Jesús ^a,b   Pelez, Teresa ^a,b   Rodrguez Crixems, Marta ^a   Torres Narbona, Marta ^a   Muoz, Patricia ^a,b   Alcal, Luis ^a   Bouza, Emilio ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Candidemia; Empirical treatment; Fluconazole resistance; Intensive care units (ICUs)

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE;

ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CLINICAL FEATURE; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NONHUMAN; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGEMIA; HUMANS; INTENSIVE CARE UNITS; RETROSPECTIVE STUDIES;

CANDIDA;

EID: 70749135974     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802415556     Document Type: Article

References (24)

1. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a populationbased active surveillance. Clin Infect Dis 1999; 29: 1164-1170.
2. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a populationbased active surveillance program. J Clin Microbiol 2004; 42: 1519-1527.
3. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-316.
4. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002; 40: 3489-3492.
5. Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9: 985-990.
6. Almirante B, Rodríguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-1835.
7. Vincent JL, Anaissie E, Bruining H, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24: 206-216.
8. Rentz A, Halpern M, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-788.
9. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
10. Cuenca-Estrella M, Rodríguez D, Almirante B, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55: 194-199.
11. Clinical and Laboratory Standards Institute. 2002. Reference Method for Broth Dilution Antifungal Susceptibility Testing Of Yeasts. Approved Standard CLSI Document M27-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003; 16: 533-537.
13. Muñoz P, Fernández-Turégano CP, Alcalá L, et al. Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole. Diagn Microbiol Infect Dis 2002; 44: 163-167.
14. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298-1302.
15. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12: 501-517.
16. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10(Suppl. 1): 11-23.
17. Pfaller MA, Messer SA, Boyken L, et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol 2004; 42: 3137-3141.
18. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-447.
19. Wilson AG, Micek ST, Ritchie DJ. A retrospective evaluation of fluconazole for the treatment of Candida glabrata fungemia. Clin Ther 2005; 27: 1228-1237.
20. Bennett JE, Izumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 2004; 48: 1773-1777.
21. Borst A, Raimer MT, Warnock DW, Morrison CJ, Arthington-Skaggs BA. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother 2005; 49: 783-787.
22. Torres HA, Kontoyiannis DP, Rolston KV. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study. Support Care Cancer 2004; 12: 511-516.
23. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
24. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.